Higher levels of daytime light exposure are associated with a lower risk for dementia, while no association was seen for nighttime light.

In response to a rising multistate outbreak of Cyclospora infections, the CDC has issued a health advisory for clinicians.

Counties across the US with limited access to radiation oncology practice sites tend to be rural and have higher levels of poverty.

The FDA accepted the NDA for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027.

Learn about notable updates that occurred in June 2026 for investigational products in development (not an inclusive list).

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics Lic ...

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

Former soccer players with a history of traumatic brain injury involving loss of consciousness may face an increased risk for ...

The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment initiation for early Alzheimer disease.

Significant productivity loss can be seen up to 15 years before early-onset dementia diagnosis, potentially explained by delays in diagnosis.

A ketogenic diet is associated with improved cognitive and psychiatric factors among adults with schizophrenia and bipolar-1 disorders.

High intake of ultra-processed foods is associated with an increased risk for cognitive impairment, particularly in adults younger than 60 years.